Landmark: Delhi HC Quashes Drug Licence Suspension Without Prior Hearing

In a significant ruling that reinforces the constitutional protection available to pharmaceutical manufacturers, the Delhi High Court in early 2026 quashed a drug manufacturing licence suspension order issued by the Delhi state drug authority. The order was set aside on the ground that the company was never given an opportunity to be heard before the suspension was imposed — a fundamental violation of the principles of natural justice. Advocate Srijan Tiwari analyses the judgment and its implications for pharmaceutical corporations.

Background: The Drug Licence Suspension Framework Under Indian Law

Drug manufacturing licences in India are issued under the Drugs and Cosmetics Act, 1940 and the Drugs and Cosmetics Rules, 1945. Under Rule 85 and related provisions, state drug licensing authorities have power to suspend or cancel manufacturing licences — but only under specific conditions and following a prescribed procedure.

The statutory framework requires that before any licence is suspended or cancelled, the licensing authority must:

• Issue a show cause notice specifying the grounds for the proposed action
• Give the licensee a reasonable opportunity to submit a written reply
• Grant a personal hearing if requested
• Consider the reply and material before the authority before passing the order
• Pass a reasoned order reflecting application of mind

Despite this clear procedural framework, state drug authorities across India — including in Delhi — regularly bypass these requirements, particularly in politically sensitive situations or where there is media pressure following a quality incident. This is where Advocate Srijan Tiwari's intervention at the Delhi High Court becomes critical.

The 2026 Delhi High Court Ruling — Key Facts and Findings

In the 2026 case, a pharmaceutical manufacturing company approached the Delhi High Court challenging a licence suspension order issued by the Assistant Drug Controller, Delhi. The company's manufacturing licence had been suspended following a drug quality complaint, but critically — the company had received no show cause notice before the suspension, no opportunity to respond, and no personal hearing.

The Delhi state drug authority contended that given the urgency of the situation and the potential public health risk posed by the quality complaint, it was entitled to suspend the licence summarily — without prior notice.

The Delhi High Court rejected this contention categorically. The Court held that:

• Natural justice is non-negotiable: The right to a hearing before an adverse order is passed is a fundamental requirement of natural justice — it cannot be waived except in the most extreme and genuinely urgent situations where delay would cause irreparable public harm.
• A quality complaint alone does not justify summary suspension: A mere complaint or allegation of drug quality failure — without testing results confirming the failure — does not constitute the kind of emergency that could justify bypassing the hearing requirement.
• Post-facto opportunity is not a cure: The authority cannot justify a summary suspension by offering to hear the company after the suspension is already in place. The right to be heard must be exercised before the order, not after.
• The suspension order was void ab initio: Because it was passed without complying with the mandatory procedural requirements, the suspension order was void from the beginning — and all actions taken pursuant to it were equally invalid.

Why This Judgment Matters for Pharmaceutical Companies

This Delhi High Court ruling is significant for several reasons that Advocate Srijan Tiwari highlights for pharmaceutical corporations:

It reaffirms constitutional protection. Pharmaceutical manufacturing licences are property rights — and the Constitution of India protects property against arbitrary state action. A drug licence suspension that violates natural justice is an unconstitutional deprivation of this right.

It creates clear grounds for immediate High Court intervention. When a licence is suspended without a prior hearing, a writ petition under Article 226 can be filed at the Delhi High Court on an urgent basis — often on the same day — seeking an interim stay of the suspension. Advocate Srijan Tiwari has obtained same-day interim stays in multiple drug licence cases at the Delhi High Court.

It puts drug authorities on notice. Drug authorities in Delhi now know that summary licence suspensions will be challenged — and will likely be quashed — if the procedural framework is not followed. This creates an incentive for authorities to follow the law, which ultimately benefits the pharmaceutical industry as a whole.

Emergency Drug Licence Challenge: What Advocate Srijan Tiwari Does

When a pharmaceutical company approaches Advocate Srijan Tiwari with an urgent drug licence suspension matter, the response is immediate. Within hours of being retained, his team:

1. Reviews the suspension order for procedural irregularities — was a show cause notice issued? Was a hearing given? Is the order reasoned?
2. Prepares an urgent writ petition under Article 226 of the Constitution before the Delhi High Court, challenging the suspension order and seeking an interim stay.
3. Moves the court on an urgent basis — often within the same day or the next day — for an interim stay that restores the company's ability to manufacture while the writ petition is heard on merits.
4. Files a detailed affidavit in support of the stay application, highlighting the procedural violations and the irreparable harm caused by the suspension to the company's operations.
5. Conducts the substantive hearing of the writ petition, marshalling legal arguments and case law in support of quashing the suspension order.

This is not work that can be effectively done by a general corporate lawyer or a criminal lawyer without drug law expertise. The intersection of constitutional law, administrative law, and the specialised statutory framework of the Drugs and Cosmetics Act requires a dedicated specialist. Advocate Srijan Tiwari is that specialist for Delhi's pharmaceutical industry.

Preventive Strategies for Drug Licence Protection

While Advocate Srijan Tiwari is equally effective at challenging illegal licence suspensions after they are imposed, the best strategy is a proactive one. He advises pharmaceutical corporations to:

• Respond to all drug authority inspections and SCNs promptly and professionally. A non-response is treated as acquiescence and reduces the company's leverage significantly.
• Retain standing drug law counsel with High Court access. When a crisis hits, having Advocate Srijan Tiwari already retained means there is no delay in getting legal help — the response is immediate.
• Maintain complete documentation of all drug authority interactions. Every inspector visit, every notice received, every response filed — all of these should be documented and filed systematically.
• Request a personal hearing proactively in responses to SCNs. Making the request in writing creates a record that the company asserted its right to a hearing — which can be used against the authority if it then proceeds to pass an order without granting one.

Drug licence under threat? Call Advocate Srijan Tiwari at 9899966225. Available same-day for urgent drug licence matters at Delhi High Court.